A retrospective matched study of 16,792 type 2 diabetes patients linked prior GLP-1 drug use to lower mortality from necrotizing soft tissue infection.
Recap by typeshit. Full story at Bioengineer.org.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
17:15
Sandy Gibson shares a personal update two months into taking tirzepatide and weighs whether it is doing its job.
Loading…